

HER2 Testing and Clinical Decision Making in Ga

American Journal of Clinical Pathology

146, 647-669

DOI: 10.1093/ajcp/aqw206

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses. Genomics, Proteomics and Bioinformatics, 2017, 15, 94-100.	3.0	8
2	Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews, 2017, 59, 1-21.	3.4	73
3	HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. Archives of Pathology and Laboratory Medicine, 2018, 142, 516-522.	1.2	10
4	Applications of Pharmacogenomics in Oncology. Advances in Molecular Pathology, 2018, 1, 115-124.	0.2	1
5	Current therapeutic landscape for advanced gastroesophageal cancers. Annals of Translational Medicine, 2018, 6, 78-78.	0.7	7
6	The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. Cells, 2019, 8, 1357.	1.8	6
7	The value of diffusion kurtosis imaging in assessing mismatch repair gene expression of rectal carcinoma: Preliminary findings. PLoS ONE, 2019, 14, e0211461.	1.1	1
8	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. Annals of Oncology, 2019, 30, 1254-1264.	0.6	20
9	The landscape of d16HER2 splice variant expression across HER2-positive cancers. Scientific Reports, 2019, 9, 3545.	1.6	22
10	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. Journal of Molecular Diagnostics, 2019, 21, 390-407.	1.2	15
11	Validation of HER2 Amplification as a Predictive Biomarker for Anti-epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-13.	1.5	46
12	Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. Journal of Immunotherapy, 2019, 42, 33-42.	1.2	41
13	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 7-15.	0.9	31
14	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	0.8	44
15	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. Gastric Cancer, 2020, 23, 579-590.	2.7	16
16	Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches. , 2021, , 317-342.		0
17	Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists Initiative. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 199-220.	1.8	0
18	Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells. Cancer Research and Treatment, 2021, 53, 457-470.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Performance of a HER2 testing algorithm specific for p53â€ abnormal endometrial cancer. <i>Histopathology</i> , 2021, 79, 533-543.	1.6	10
20	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021, 22, 703-726.	0.6	3
21	Practical considerations in screening for genetic alterations in cholangiocarcinoma. <i>Annals of Oncology</i> , 2021, 32, 1111-1126.	0.6	77
22	Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times. <i>World Journal of Clinical Cases</i> , 2019, 7, 419-430.	0.3	5
23	The dynamics of HER2 status in esophageal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 26787-26799.	0.8	17
24	Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study. <i>Iranian Biomedical Journal</i> , 2020, 24, 47-53.	0.4	6
25	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , 2021, 13, 44.	1.7	40
26	The Relationship Between HER-2 Expression Levels and ¹⁸F-FDG PET/CT Parameters in Gastric Cancer. <i>Molecular Imaging and Radionuclide Therapy</i> , 2021, 30, 150-157.	0.3	2
27	RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. <i>Modern Pathology</i> , 2021, , .	2.9	0
28	Robust Anti-tumor Response in a Patient with Metastatic Gastroesophageal Junction Adenocarcinoma on Long-term Maintenance Chemotherapy With Trastuzumab Alone: An Unusual Occurrence. <i>Cureus</i> , 2020, 12, e11472.	0.2	0
30	Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. <i>Pathology and Oncology Research</i> , 2022, 28, 1610293.	0.9	3
31	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 200-223.	0.5	7
32	Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	1
33	Tailoring antiHer2 treatment strategies in breast cancer and beyond. <i>Current Problems in Cancer</i> , 2022, 46, 100892.	1.0	4
34	Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2022, 127, 2198-2206.	2.9	2
35	Immune Checkpoint Inhibitors combined with HER-2 targeted therapy in HER-2 positive Gastroesophageal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103864.	2.0	3
36	Barrettâ€™s Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective. <i>Thoracic Surgery Clinics</i> , 2022, 32, 413-424.	0.4	0
37	Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 107.	0.1	0

#	ARTICLE	IF	CITATIONS
38	Assessment of HER2 in Gastric-Type Endocervical Adenocarcinoma and its Prognostic Significance. Modern Pathology, 2023, 36, 100148.	2.9	2
39	Considerations in comparing intestinal and diffuse type gastric adenocarcinomas. Helicobacter, 2023, 28, .	1.6	3